These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8416600)

  • 1. Iron, melanin and dopamine interaction: relevance to Parkinson's disease.
    Ben-Shachar D; Youdim MB
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):139-50. PubMed ID: 8416600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.
    Ben-Shachar D; Riederer P; Youdim MB
    J Neurochem; 1991 Nov; 57(5):1609-14. PubMed ID: 1919577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
    Ben-Shachar D; Youdim MB
    J Neural Transm Suppl; 1990; 29():251-8. PubMed ID: 2193109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease.
    Ben-Shachar D; Eshel G; Riederer P; Youdim MB
    Ann Neurol; 1992; 32 Suppl():S105-10. PubMed ID: 1510367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron-binding characteristics of neuromelanin of the human substantia nigra.
    Double KL; Gerlach M; Schünemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MB; Riederer P; Ben-Shachar D
    Biochem Pharmacol; 2003 Aug; 66(3):489-94. PubMed ID: 12907248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB; Riederer P
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation.
    Korytowski W; Sarna T; Zar ba M
    Arch Biochem Biophys; 1995 May; 319(1):142-8. PubMed ID: 7771778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
    Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
    J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
    D'Amato RJ; Lipman ZP; Snyder SH
    Science; 1986 Feb; 231(4741):987-9. PubMed ID: 3080808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
    Youdim MB; Ben-Shachar D; Riederer P
    Acta Neurol Scand Suppl; 1989; 126():47-54. PubMed ID: 2618593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E; Puchinger L; Jellinger K; Linert W; Stachelberger H; Jameson RF
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
    Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
    Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E; Graybiel AM; Agid YA
    Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.
    Kooncumchoo P; Sharma S; Porter J; Govitrapong P; Ebadi M
    J Mol Neurosci; 2006; 28(2):125-41. PubMed ID: 16679553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?
    Herrero MT; Hirsch EC; Kastner A; Ruberg M; Luquin MR; Laguna J; Javoy-Agid F; Obeso JA; Agid Y
    Neuroscience; 1993 Sep; 56(2):499-511. PubMed ID: 8247275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
    Han J; Cheng FC; Yang Z; Dryhurst G
    J Neurochem; 1999 Oct; 73(4):1683-95. PubMed ID: 10501216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium species with synthetic dopamine-melanin.
    Wu EY; Chiba K; Trevor AJ; Castagnoli N
    Life Sci; 1986 Nov; 39(18):1695-700. PubMed ID: 3490611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
    Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.